Total share-based expense related to stock options and RSUs was approximately $28,000 and $0.1 million for the three months ended September 30, 2024 and 2023, respectively, and approximately $0.1 million and $0.2 million for each of the nine months ended September 30, 2024 and 2023.

Share-based expense is classified in the condensed consolidated statements of operations as follows:

Employee Stock Options and RSUs

During the nine months ended September 30, 2024, 20,000 stock options to purchase shares of common stock were granted by the Company. No stock options to purchase shares of common stock were granted during the three months ended September 30, 2024. No stock option awards to purchase shares of common stock were granted during the three and nine months ended September 30, 2023. No RSUs were granted during each of the three and nine months ended September 30, 2024 and 2023. The Company recognized a total of approximately $28,000 and $0.1 million of share-based expense related to employee stock options during the three months ended September 30, 2024 and 2023, respectively, and $0.1 million and $0.2 million during the nine months ended September 30, 2024 and 2023, respectively. The Company issued 417 shares of common stock during the nine months ended September 30, 2024 related to RSUs representing all the RSUs outstanding. As a result, no RSUs were outstanding at September 30, 2024. No employee stock options were exercised during the three and nine months ended September 30, 2024 and 2023. During each of the three and nine months ended September 30, 2024 stock options to purchase 20,847 shares of common stock were cancelled and, during the nine months ended September 30, 2024, stock options to purchase 11,667 shares of common stock were forfeited. No employee stock options expired during the three and nine months ended September 30, 2023.

Non-Employee Stock Options

There were no non-employee stock options granted or exercised during the three and nine months ended September 30, 2024 and 2023, respectively. No non-employee stock option grants expired during the three and nine months ended September 30, 2024. During the nine months ended September 30, 2023, non-employee stock option grants to purchase approximately 100 shares of common stock expired. The Company did not recognize any expense related to non-employee stock options during the three and nine months ended September 30, 2024 and 2023, respectively.